Alacepril

• CAT Number: I001689
• CAS Number: 74258-86-9
• Molecular Formula: C20H26N2O5S
• Molecular Weight: 406.497
• Purity: ≥95%
• Target: Angiotensin-Converting Enzyme Inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4°Cfor short term (days to weeks), or -20 °C for long term (months).
• IUPAC Name: (2S)-2-[[(2S)-1-[(2S)-3-acetylsulfanyl-2-methylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
• InChI: InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13-,16+,17+/m1/s1
• InChIKey: FHHHOYXPRDYHEZ-COXVUDFISA-N
• SMILES: CC(CSC(=O)C)C(=O)N1CCCC1C(=O)NC(CC2=CC=CC=C2)C(=O)O

Alacepril (CAT: I001689), also known as Cetapril and DU-1219, is an angiotensin-converting enzyme (ACE) inhibitor. It is commonly used as an antihypertensive medication. Alacepril works by inhibiting the action of ACE, which is responsible for converting angiotensin I to angiotensin II, a potent vasoconstrictor. By blocking this conversion, Alacepril helps to relax and widen blood vessels, leading to a reduction in blood pressure. This mechanism of action makes it effective in the treatment of hypertension and can also be used in the management of certain heart conditions.

Reference

1:Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs. Sakatani A, Miyagawa Y, Takemura N.J Vet Cardiol. 2016 Sep;18(3):248-54. doi: 10.1016/j.jvc.2016.05.001. Epub 2016 Jun 27. PMID: 27364087 2:Pharmacodynamics of alacepril in healthy cats. Sugimoto K, Fujii Y, Takubo I, Shiga T, Sunahara H, Aoki T, Orito K.J Feline Med Surg. 2016 Feb 29. pii: 1098612X16636420. [Epub ahead of print] PMID: 26927816 3:[Successful extubation in a patient with alacepril-induced tongue angioedema]. Katoh H, Itagaki T, Suzuki K, Obata Y, Adachi Y, Doi M, Sato S.Masui. 2010 Apr;59(4):519-22. Japanese. PMID: 20420150 4:Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure. Nonoguchi H, Kiyama S, Kitamura K, Naruse M, Tomita M, Tazoe N, Tajiri M, Nakayama Y, Kohda Y, Inoue T, Tomita K.Hypertens Res. 2008 Jan;31(1):29-36. doi: 10.1291/hypres.31.29. PMID: 18360015 5:The inhibitory effect of alacepril, an angiotensin-converting enzyme inhibitor, on endothelial inflammatory response induced by oxysterol and TNF-alpha. Shimozawa M, Naito Y, Manabe H, Uchiyama K, Katada K, Kuroda M, Nakabe N, Yoshida N, Yoshikawa T.Redox Rep. 2004;9(6):354-9. PMID: 15720832 6:Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril. Usui S, Kubota M, Iguchi K, Kiho T, Sugiyama T, Katagiri Y, Hirano K.Pharm Res. 2003 Aug;20(8):1309-16. PMID: 12948030 7:Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild-to-moderate heart failure. Kinugawa T, Osaki S, Kato M, Ogino K, Shimoyama M, Tomikura Y, Igawa O, Hisatome I, Shigemasa C.Clin Exp Pharmacol Physiol. 2002 Dec;29(12):1060-5. PMID: 12390293 8:Effects of acute and chronic alacepril treatment on exercise capacity and hemodynamics in patients with heart failure: a preliminary study. Osaki S, Kinugawa T, Ogino K, Kato M, Furuse Y, Tomikura Y, Igawa O, Hisatome, Shigemasa C.Int J Clin Pharmacol Ther. 2002 Feb;40(2):69-74. PMID: 11862975 9:Spatial and temporal analysis of left ventricular filling flow propagation in hypertensive patients before and after regression of myocardial hypertrophy with alacepril therapy. Nobuoka S, Nagashima J, Hatano S, Fujimaki R, Saito K, Tokuoka S, Ando H, Miyake F.Echocardiography. 2001 Aug;18(6):479-83. PMID: 11567592 10:Effects of alacepril and amlodipine on the renal injury induced by a high-cholesterol diet in rats. Atarashi K, Takagi M, Minami M, Ishiyama A.J Hypertens. 1999 Dec;17(12 Pt 2):1983-6. PMID: 10703899